glp 1 being discontinued FDA Ban on Compounded GLP-1 Drugs: What to Know FDA says that the GLP-1

Adding GIP receptor (GIPR) agonism introduces a second incretin pathway that enhances insulin secretion through distinct cAMP signaling, independently modulates adipocyte lipid handling, and engages central appetite circuits through complementary routes to GLP-1R

Knowing these interactions is key to working with your healthcare provider to create a treatment plan that works for you

But for triathletes, the conversation cannot stop at body weight alone

Wellstar Center for Health Equity partners with local faith communities to support their health and wellness programs

Expanding Indications: Beyond Obesity and Diabetes The GLP-1 drug pipeline in 2026 reaches well beyond weight management and glycaemic control